The CE-marked system’s design eliminates the electric or battery powered pump typically used in negative-pressure wound therapy.
Spiracur president and CEO Gary Restani said that he expected the study to "add to the growing body of literature highlighting the importance of different wound care treatment choices".
Cardiff University School of Medicine Innovation, Methodologies and Engagement Institute for Translation director and study principal investigator Keith Harding and his co-investigators will evaluate the efficacy of the SNaP system for treating difficult-to-heal lower extremity wounds.
"We are eager to apply this device to patients who are candidates for negative-pressure wound therapy devices in the UK, as we believe the SNaP System may redefine how chronic wounds are treated," Harding added.
The final results of the prospective study are expected in early 2013.